Business Medical Dialogues
    • facebook
    • twitter
    Login Register
    • facebook
    • twitter
    Login Register
    • Medical Dialogues
    • Speciality Dialogues
    • Education Dialogues
    • Medical Jobs
    • Medical Matrimony
    • MD Brand Connect
    Business Medical Dialogues
    • News
        • Financial Results
        • Hospitals & Diagnostics
        • IT / Health Venture
        • Implants / Devices
        • Insurance
        • Key Movement
        • Pharmaceuticals
        • Policy
        • Technology
        • pharma-news
    • blog
    LoginRegister
    Business Medical Dialogues
    LoginRegister
    • Home
    • News
      • Financial Results
      • Hospitals & Diagnostics
      • IT / Health Venture
      • Implants / Devices
      • Insurance
      • Key Movement
      • Pharmaceuticals
      • Policy
      • Technology
      • pharma-news
    • blog
    • Home
    • News
    • pharma-news
    • Zydus Cadila gets DGCI...

    Zydus Cadila gets DGCI nod for diabetes drug Saroglitazar Magnesium

    Farhat NasimWritten by Farhat Nasim Published On 2020-02-04T10:30:44+05:30  |  Updated On 4 Feb 2020 10:31 AM IST
    Zydus Cadila gets DGCI nod for diabetes drug Saroglitazar Magnesium

    "Zydus Cadila has received the approval from the Drug Controller General of India (DCGI) for use of Saroglitazar Mg in the treatment of type II diabetes mellitus as add-on therapy with Metformin," the drug firm said in a filing to BSE.

    New Delhi: Drug firm Zydus Cadila on Monday said that it has received approval from Drug Controller General of India (DGCI) for Saroglitazar Magnesium used in the treatment of diabetes.

    "Zydus Cadila has received the approval from the Drug Controller General of India (DCGI) for use of Saroglitazar Mg in the treatment of type II diabetes mellitus as add-on therapy with Metformin," the drug firm said in a filing to BSE.

    Type II diabetes is a condition in which cells cannot use blood sugar (glucose) efficiently for energy.

    In India, the drug was previously approved in 2013 for the treatment of hypertriglyceridemia and diabetic dyslipidemia.

    Also Read: Zydus Cadila Wins DCGI Nod For Marketing Rabies Drug Twinrab

    More than one million patients are being treated with Saroglitazar (Lipaglyn).

    "Insulin resistance is one of the primary causes of diabetes and there is a huge unmet medical need for a safe and effective insulin sensitizer. Saroglitazar is an important scientific and medical breakthrough in our effort to develop medicines for patients suffering from type 2 diabetes mellitus," Zydus Group Chairman Pankaj Patel said.

    With increasing cases of diabetes in India, the need to strengthen diabetes management and help patients control their blood sugar levels is of critical importance, he said.

    Also Read: Zydus Cadila Files NDA With DCGI For Liver Disease Drug Saroglitazar Magnesium

    Source : PTI

    Disclaimer: This site is primarily intended for healthcare professionals. Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription. Use of this site is subject to our terms of use, privacy policy, advertisement policy. © 2020 Minerva Medical Treatment Pvt Ltd

    Farhat Nasim
    Farhat Nasim

      Farhat Nasim joined Medical Dialogue an Editor for the Business Section in 2017. She Covers all the updates in the Pharmaceutical field, Policy, Insurance, Business Healthcare, Medical News, Health News, Pharma News, Healthcare and Investment. She is a graduate of St.Xavier’s College Ranchi. She can be contacted at editorial@medicaldialogues.in Contact no. 011-43720751 To know about our editorial team click here

      Show Full Article
      Next Story
      Similar Posts
      NO DATA FOUND

      Popular Stories

      • Email: info@medicaldialogues.in
      • Phone: 011 - 4372 0751

      Website Last Updated On : 13 Oct 2022 5:14 AM GMT
      Company
      • About Us
      • Contact Us
      • Our Team
      • Reach our Editor
      • Feedback
      • Submit Article
      Ads & Legal
      • Advertise
      • Advertise Policy
      • Terms and Conditions
      • Privacy Policy
      • Editorial Policy
      • Comments Policy
      • Disclamier
      Medical Dialogues is health news portal designed to update medical and healthcare professionals but does not limit/block other interested parties from accessing our general health content. The health content on Medical Dialogues and its subdomains is created and/or edited by our expert team, that includes doctors, healthcare researchers and scientific writers, who review all medical information to keep them in line with the latest evidence-based medical information and accepted health guidelines by established medical organisations of the world.

      Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription.Use of this site is subject to our terms of use, privacy policy, advertisement policy. You can check out disclaimers here. © 2025 Minerva Medical Treatment Pvt Ltd

      © 2025 - Medical Dialogues. All Rights Reserved.
      Powered By: Hocalwire
      X
      We use cookies for analytics, advertising and to improve our site. You agree to our use of cookies by continuing to use our site. To know more, see our Cookie Policy and Cookie Settings.Ok